Hims & Hers Health cut its 2026 adjusted EBITDA forecast after third-quarter revenue rose 49%, while the telehealth company swung to a $33 million net loss from a year-earlier profit.
In its Nov. 9 results, the company set its full-year adjusted EBITDA range at $257 million to $277 million, down from $275 million to $325 million in its Aug. 10 forecast. It also narrowed its revenue outlook to $3.13 billion to $3.15 billion, from $3.1 billion to $3.3 billion. The new revenue range spans $20 million, compared with $200 million previously.
Revenue for the quarter ended Sept. 30 was $890.4 million. Net income of $15.8 million in the same quarter of 2025 gave way to a $33 million loss. Quarterly adjusted EBITDA was $82.4 million, up from $78.4 million a year earlier.
The revised full-year outlook implies an adjusted EBITDA margin of 8% to 9%, compared with 9% to 10% under the previous forecast. For the fourth quarter, Hims & Hers projected revenue of $875 million to $895 million and adjusted EBITDA of $70 million to $90 million.
Chief Financial Officer Yemi Okupe said the company was managing marketing outlays ahead of planned platform rollouts in the fourth quarter. He said the expansions were intended to position the business for 2027.
The company identifies adjusted EBITDA as a non-GAAP measure. It said it did not provide a forward-looking comparison with net income because some reconciliation inputs were too uncertain to estimate.
